TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 977134
Drug: Griseofulvin tablets
Normalized name: Griseofulvin Tablets
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin tablets only
Study: 31965616
Drug: Detomidine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (0.03 mg/kg bwt)
Study: 31965616
Drug: Xylazine (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (1.1 mg/kg bwt)
Study: 27732034
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT) + Work Therapy
Study: 27732034
Drug: Work Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work Therapy (Control)
Study: 23121002
Drug: Psychoeducative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducative group therapy (six sessions during pregnancy and one after childbirth)
Study: 23121002
Drug: Psychoeducative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducative group therapy (n = 90 participants)
Study: 23121002
Drug: Psychoeducative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducative group therapy
Study: 15503108
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 400 mg/d titrated to 1200 mg/d, then maintained or increased to 2400 mg/d or 3600 mg/d if not beneficial
Study: 2894070
Drug: Azo compounds
Normalized name: Azo
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azo compounds (sulphasalazine and olsalazine)
Study: 2894070
Drug: Slow-release compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release compounds (Pentasa, Asacol, and Salofalk)
Study: 2894070
Drug: Azo compounds
Normalized name: Azo
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azo compounds
Study: 2894070
Drug: Slow-release compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release compounds
Study: 28648148
Drug: Debt advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debt advice provided by the CAB, treatment as usual (TAU), and two debt advice leaflets.
Study: 18317194
Drug: ProDisc-L lumbar
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProDisc-L lumbar disc replacement
Study: 12706031
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention program
Study: 15321209
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of epidural bupivacaine (0.25%) at cervical dilatation <4 cm
Study: 15321209
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of epidural bupivacaine (0.25%) at cervical dilatation >=4 cm
Study: 31805247
Drug: Phonomotor treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonomotor treatment (56-60 hr over 6 weeks)
Study: 31805247
Drug: Semantic Feature
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semantic Feature Analysis (SFA) treatment (56-60 hr over 6 weeks)
Study: 27836235
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery (using a model-predictive control algorithm to direct subcutaneous delivery of rapid-acting insulin analogue without meal-time insulin boluses)
Study: 27836235
Drug: Conventional subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subcutaneous insulin delivery according to local clinical guidelines
Study: 24953206
Drug: Triple boceprevir-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple boceprevir-based antiviral therapy
Study: 19277904
Drug: IA TPA
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA TPA (22 mg over 2 h)
Study: 17318803
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of gentamicin (antibiotic)
Study: 11443568
Drug: Meningococcal C
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal C conjugate (MCC) vaccine after MACP vaccination
Study: 9860404
Drug: Pentoxifylline (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1.4 mg/kg BW, n = 10 patients)
Study: 9860404
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% solution (n = 10 patients)
Study: 2707048
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g intravenously pre‐operatively)
Study: 2707048
Drug: Clavulanate-potentiated amoxycillin
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clavulanate-potentiated amoxycillin (1200 mg, repeated for 2 more doses if necessary)
Study: 883332
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for patients with histologically positive axillary nodes
Study: 21385249
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (one-hour single music session)
Study: 19023677
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 IV over 10 min and gemcitabine 800 mg/m2 IV at 10 mg/m2 per minute on days 1 and 15 of an every-4-weeks schedule with vitamin B12 and folate supplementation
Study: 15017629
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with a proton pump inhibitor (PPI), amoxicillin, and clarithromycin; Omeprazole 20 mg or Lansoprazole 30 mg twice daily; Clarithromycin 200 mg 3 times daily; Amoxicillin 500 mg 3 times daily for 1 week
Study: 9568665
Drug: Open plug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open plug and patch repair
Study: 1774727
Drug: Patient-controlled infuser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled infuser system (2.0 mg incremental dose with a 10-minute lock-out interval)
Study: 1774727
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injections (10-15 mg every three hours)
Study: 6167759
Drug: Bleomycin in
Normalized name: bleomycin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin in addition to conventional four drug regimen (vincristine, adriamycin, cyclophosphamide, actinomycin D)
Study: 30576030
Drug: Present‐Centered Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present‐Centered Therapy (PCT)
Study: 30944103
Drug: rhNGF eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhNGF eye drops at 20 μg/mL (Group 1: G1)
Study: 30944103
Drug: rhNGF eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhNGF eye drops at 4 μg/mL (Group 2: G2)
Study: 26030354
Drug: Oral vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccination with live attenuated E. ictaluri isolate (1:100 dilution, ∼5 × 10⁶ CFU/g of feed)
Study: 26030354
Drug: Oral vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccination with live attenuated E. ictaluri isolate (1:10 dilution, ∼5 × 10⁷ CFU/g of feed)
Study: 21314226
Drug: CAD/DM Smart
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD/DM Smart Form (on-treatment analysis)
Study: 21314226
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (on-treatment analysis)
Study: 15973964
Drug: DHEA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (25 mg twice daily)
Study: 15973964
Drug: DHEA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (25 mg twice daily) after exercise
Study: 8961776
Drug: High-dose gepirone-ER
Normalized name: gepirone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gepirone-ER (20-100 mg)
Study: 8961776
Drug: Low-dose gepirone-ER
Normalized name: gepirone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose gepirone-ER (10-50 mg)
Study: 1383622
Drug: Ranolazine 240
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 240 mg
Study: 1383622
Drug: Ranolazine plasma
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine plasma levels above 500 ng/ml
Study: 1383622
Drug: Ranolazine plasma
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine plasma levels below 500 ng/ml
Study: 25394855
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg/day) plus aspirin (100 mg/day)
Study: 25131413
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral care protocol (twice a day including tooth brushing, tongue brushing, flossing, mouth rinse, and lip care)
Study: 25131413
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral care practices
Study: 25131413
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral care protocol
Study: 22321916
Drug: Internet-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-administered cognitive behavioural therapy (ICBT), tailored according to symptom profile.
Study: 3069486
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg daily)
Study: 12074359
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg daily)
Study: 3771812
Drug: Erythromycin (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (333 mg tid)
Study: 30067745
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral (DAA) therapy
Study: 24217262
Drug: Continuous ventilation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ventilation (5 ml/kg tidal volume, 5/min frequency, zero end-expiratory pressure)
Study: 16525677
Drug: Lymphokine-activated killer
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lymphokine-activated killer (LAK) cell therapy
Study: 16525677
Drug: Esophagectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esophagectomy without LAK cell therapy
Study: 9107083
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of recombinant human erythropoietin (rhEpo) 500 U/kg/day for 30 days after transplant
Study: 1347258
Drug: Cicloprolol (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloprolol (oral, once a day for 2 weeks)
Study: 31392840
Drug: Insulin tregopil
Normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin tregopil administered 10 to 20 minutes before a meal
Study: 31392840
Drug: Insulin tregopil
Normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin tregopil with a 6-hour between-meal interval
Study: 31392840
Drug: Insulin tregopil
Normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin tregopil 4-hour group during afternoon meal
Study: 31392840
Drug: Insulin tregopil
Normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin tregopil
Study: 25903783
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of adequate antimicrobial treatment
Study: 25903783
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of adequate antimicrobial treatment
Study: 16723783
Drug: Pilsicainide 50
Normalized name: Pilsicaïnide
DrugBank: Pilsicainide (DB12712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilsicainide 50 mg t.i.d. for 2 weeks
Study: 8324212
Drug: Rifampicin 450
Normalized name: Rifampicin 450 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 450 mg + INH 300 mg
Study: 8324212
Drug: Rifampicin 450
Normalized name: Rifampicin 450 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 450 mg + INH 300 mg + pyrazinamide 1500 mg
Study: 30326632
Drug: Foxtail millet
Normalized name: Foxtail millet specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foxtail millet (50 g/day) for 12 weeks
Study: 27638495
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (continuing on the waitlist without hand therapy intervention)
Study: 24068456
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist treatment for 6 months
Study: 20457959
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist treatment
Study: 10588299
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin and mineral supplements for AMD
Study: 10588299
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin supplements for cataract
Study: 8912734
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 400 microg/d for 7 days
Study: 1713753
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma (FFP) therapy (8 units daily for 3 days)
Study: 6347109
Drug: Dexamethasone sodium
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone sodium phosphate (10 mg) administered intravenously
Study: 9701719
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously
Study: 19247842
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of IPP and VPP peptides
Study: 19247842
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of IPP and VPP peptides
Study: 19247842
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of IPP and VPP peptides
Study: 11706093
Drug: beta-interferon-1a (betaINF1a)
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: beta-interferon-1a (betaINF1a) administered IM once a week at a dose of 30 microg for 24 weeks
Study: 7619105
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Ca/d as calcium carbonate
Study: 2908803
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of ketazolam daily for 15 days
Study: 2908803
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of ketazolam continued for a further 15 days for responders
Study: 30900575
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (1.25 g for 5 days)
Study: 30900575
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline (4 g for 30 days)
Study: 21985258
Drug: Cognitive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive group therapy (CGT)
Study: 21985258
Drug: Focused psychodynamic
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused psychodynamic group therapy (FGT)
Study: 11779591
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 12.5 mg/d for 6 months
Study: 11779591
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (ethinyl estradiol 0.02 mg and desogestrel 0.15 mg) for 6 months
Study: 2680085
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg once daily at bedtime for six weeks
Study: 31166952
Drug: Biannual oral
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual oral azithromycin (20mg/kg for children, 1 g for adults)
Study: 31166952
Drug: No programmatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No programmatic antibiotics (control group)
Study: 23158886
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment for 14 days (S-14)
Study: 23158886
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment for 10 days (S-10)
Study: 23158886
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for 14 days (T-14)
Study: 11408326
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant patients
Study: 8514613
Drug: ACT group
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT group (20 mg/m2 adriamycin i.v. on days 1 and 8, 100 mg cyclophosphamide p.o. on days 1-14, 20 mg tamoxifen p.o. daily)
Study: 8514613
Drug: ACM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACM group (20 mg/m2 adriamycin i.v. on days 1 and 8, 100 mg cyclophosphamide p.o. on days 1-14, 1200 mg medroxyprogesterone acetate p.o. daily)
Study: 18491
Drug: SCH 16134
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 16134 (new benzodiazepine hypnotic)
Study: 28359716
Drug: O-3FA ethyl
Normalized name: Ethyl o-hydroxybenzoate
DrugBank: Ethyl salicylate (DB15576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-3FA ethyl esters (750 mg/d DHA and 1860 mg/d EPA)
Study: 22199129
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with fish oil (783 mg DHA, 162 mg EPA), bilberry extract (59 mg anthocyanidin), and lutein (17.5 mg) for 4 weeks
Study: 15383019
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of iron(II) daily (Group A after first three donations)
Study: 15383019
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of iron(II) daily (Group B after second three donations)
Study: 15383019
Drug: Placebo (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (both treatment groups during placebo phase)
Study: 11296070
Drug: Piracetam therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam therapy (80‐100 mg/kg per day)
Study: 11296070
Drug: Piracetam therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam therapy
Study: 8796815
Drug: Naloxone 1
Normalized name: naloxone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 1 or 4 mg
Study: 6147080
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bucindolol and Hydrochlorothiazide
Study: 29953055
Drug: Tonsilgon-N (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsilgon-N (25 droplets thrice daily for 30 days) combined with 10 sessions of lagune cleansing using Tonsillor apparatus for 30 days
Study: 27238057
Drug: Idebenone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (900 mg/day)
Study: 24576440
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of dexamethasone 4 mg/1 mL on the inferior alveolar nerve during BSSO surgery
Study: 20080545
Drug: Tailor-made notched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailor-made notched music treatment
Study: 20080545
Drug: Placebo notched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo notched music treatment
Study: 17490472
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic medication
Study: 17490472
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic medication
Study: 12410072
Drug: Thrice-daily (TID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily (TID) regimen of methylphenidate (MPH)
Study: 1974206
Drug: epanolol 200
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol 200 mg daily for 7 days
Study: 22304887
Drug: 8-day intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-day intensive treatment for panic disorder (PDA)
Study: 16091146
Drug: Apple Juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple Juice (AJ) 15 ml/kg twice daily
Study: 16091146
Drug: White Grape
Normalized name: Herbal Essences White Grapefruit Shampoo
DrugBank: Wine grape (DB10634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White Grape Juice (WGJ) 15 ml/kg twice daily
Study: 10702653
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg titrated to Losartan 50 mg/Hydrochlorothiazide (HCT) 12.5 mg (n = 11)
Study: 10702653
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg titrated to 10 mg (n = 14)
Study: 8590958
Drug: GHRH‐antagonist (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH‐antagonist (100 micrograms/100 ml saline over 75 min) administered in the morning
Study: 8590958
Drug: GHRH‐antagonist (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH‐antagonist (100 micrograms/100 ml saline over 75 min) administered in the evening
Study: 1717206
Drug: solution enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution enriched with branched chain amino acid (45% BCAA)